2. Seshasai SR, Kaptoge S, Thompson A et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829–41.
3. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013; 56: 686–95.
4. Liu J, Grundy SM, Wang W et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007; 153: 552–8.
5. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012; 126: 1301–13.
6. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765–75.
7. Catapano AL, Graham I, De Backer G et al; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–3058. DOI: 10.1093/eurheartj/ehw272
8. Scott R, O’Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9.795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493–8.
9. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very lowdensity lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225–36.
10. Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015; 239: 483–95.
11. Kearney PM, Blackwell L, Collins R et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18.686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371 (9607): 117–25. DOI: 10.1016/S0140-6736(08)60104-X
12. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28 (1): 88–136.
13. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46 (7): 1225–8. 
14. LaRosa JC, Grundy SM, Waters DD et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35. 
15. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301–7.
16. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615–22.
17. Ridker PM, Danielson E, Fonseca FA et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207. DOI: 10.1056/NEJMoa0807646
18. De Vries FM, Denig P, Pouwels KB et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012; 72 (18): 2365–73. DOI: 10.2165/11638240-000000000-00000
19. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии. 2017; 3: 5–22. / Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. Ateroskleroz i dislipidemii. 2017; 3: 5–22. [in Russian]
20. Betteridge DJ, Gibson JM, Sager PT. Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study). Am J Cardiol 2007; 100: 1245–8.
21. Wolffenbuttel BHR, Franken AAM, Vincent HH on behalf of the DUTCH CORALL study group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J In Med 2005; 257: 531–9.
22. Sorof J, Berne Ch, Siewert-Delle A et al on behalf of the URANUS study investigators. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diab Res Clin Practice 2006; 72: 81–7.
23. Karlson BW, Palmer MK, Nicholls SJ et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol 2016; 117 (9): 1444–8. DOI: 10.1016/j.amjcard.2016.02.011
24. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available at: www.fda.gov/drugs/drugsafety/ucm293101.htm
25. Zhou Y, Yuan Y, Cai RR et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother 2013; 14 (12): 1575–84.
26. Astra Zeneca. Clinical briefing document – Endocrine and Metabolic Drugs Advisory Committee meeting for rosuvastatin (Crestor). Available at: www.fda.gov/downloads/advisorycommittees/committe esmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisory committee/ucm193831.pdf
27. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 75: 735–42.
28. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305 (24): 2556–64.
29. Кобалава Ж.Д., Виллевальде С.В. Терапия статинами и риск развития сахарного диабета. Эффективная фармакотер. Эндокринология. Спецвып. 2015; 11: 33–9. / Kobalava Zh.D., Villeval'de S.V. Terapiia statinami i risk razvitiia sakharnogo diabeta. Effektivnaia farmakoter. Endokrinologiia. Spetsvyp. 2015; 11: 33–9. [in Russian]
30. Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57 (14): 1535–45. DOI: 10.1016/j.jacc.2010.10.047
31. Ruscica M, Macchi C, Morlotti B et al. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med 2014; 25 (5): 401–6.
32. Mora S, Glynn RJ, Hsia J et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121 (9): 1069–77.
33. Puurunen J, Piltonen T, Puukka K et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013; 98 (12): 4798–807. 
34. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172 (2): 144–52. 
35. Ridker PM, Pradhan A, MacFadyen JG et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380 (9841): 565–71.

________________________________________________

1. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrin 2014; 2: 56–64.
2. Seshasai SR, Kaptoge S, Thompson A et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829–41.
3. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013; 56: 686–95.
4. Liu J, Grundy SM, Wang W et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007; 153: 552–8.
5. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012; 126: 1301–13.
6. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765–75.
7. Catapano AL, Graham I, De Backer G et al; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–3058. DOI: 10.1093/eurheartj/ehw272
8. Scott R, O’Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9.795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493–8.
9. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very lowdensity lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225–36.
10. Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015; 239: 483–95.
11. Kearney PM, Blackwell L, Collins R et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18.686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371 (9607): 117–25. DOI: 10.1016/S0140-6736(08)60104-X
12. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28 (1): 88–136.
13. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46 (7): 1225–8. 
14. LaRosa JC, Grundy SM, Waters DD et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35. 
15. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301–7.
16. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615–22.
17. Ridker PM, Danielson E, Fonseca FA et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207. DOI: 10.1056/NEJMoa0807646
18. De Vries FM, Denig P, Pouwels KB et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012; 72 (18): 2365–73. DOI: 10.2165/11638240-000000000-00000
19. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. Ateroskleroz i dislipidemii. 2017; 3: 5–22. [in Russian]
20. Betteridge DJ, Gibson JM, Sager PT. Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study). Am J Cardiol 2007; 100: 1245–8.
21. Wolffenbuttel BHR, Franken AAM, Vincent HH on behalf of the DUTCH CORALL study group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J In Med 2005; 257: 531–9.
22. Sorof J, Berne Ch, Siewert-Delle A et al on behalf of the URANUS study investigators. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diab Res Clin Practice 2006; 72: 81–7.
23. Karlson BW, Palmer MK, Nicholls SJ et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol 2016; 117 (9): 1444–8. DOI: 10.1016/j.amjcard.2016.02.011
24. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available at: www.fda.gov/drugs/drugsafety/ucm293101.htm
25. Zhou Y, Yuan Y, Cai RR et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother 2013; 14 (12): 1575–84.
26. Astra Zeneca. Clinical briefing document – Endocrine and Metabolic Drugs Advisory Committee meeting for rosuvastatin (Crestor). Available at: www.fda.gov/downloads/advisorycommittees/committe esmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisory committee/ucm193831.pdf
27. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 75: 735–42.
28. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305 (24): 2556–64.
29. Kobalava Zh.D., Villeval'de S.V. Terapiia statinami i risk razvitiia sakharnogo diabeta. Effektivnaia farmakoter. Endokrinologiia. Spetsvyp. 2015; 11: 33–9. [in Russian]
30. Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57 (14): 1535–45. DOI: 10.1016/j.jacc.2010.10.047
31. Ruscica M, Macchi C, Morlotti B et al. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med 2014; 25 (5): 401–6.
32. Mora S, Glynn RJ, Hsia J et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121 (9): 1069–77.
33. Puurunen J, Piltonen T, Puukka K et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013; 98 (12): 4798–807. 
34. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172 (2): 144–52. 
35. Ridker PM, Pradhan A, MacFadyen JG et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380 (9841): 565–71.
36. Yoon JS, Lee HW. Diabetogenic effect of statins: a double-edged sword? Diabetes Metab J 2013; 37 (6): 415–22.

О.Д.Остроумова

________________________________________________

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubet-skaia, d. 8, str. 2
ostroumova.olga@mail.ru